On 15 May 2009, orphan designation (EU/3/09/635) was granted by the European Commission to United Therapeutics Europe Ltd, United Kingdom, for treprostinil diethanolamine for the treatment of systemic sclerosis.
The sponsorship was transferred to Unither Therapeutik GmbH, Germany, in February 2019.
The sponsor's address was updated in July 2021.
Treatment of systemic sclerosis
|Date of designation||
|Orphan designation status||
|EU designation number||
Sponsor's contact details
Unither Therapeutik GmbH
Offenbach Am Main 63071
Tel: +49 69 98535179
For contact details of patients’ organisations whose activities are targeted at rare diseases, see: